essence study semaglutide In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly improved liver histologic results at 72 weeks. Full trial results and Research Alimentary Pharmacology & Therapeutics |

doi: 10.3389/fphar.2025.1610793 Received 12 April 2025 Accepted 21 July 2025 Published 18 August 2025 Volume 16 - 2025 Edited by Michael Heinrich, University College London, United Kingdom Reviewed by Sena Ardicli, Bursa Uluda University, Trkiye Huiwen Pang, University of Queensland, Australia Updates Copyright 2025 Zedan, El-Moslemany, Bahnasy, Eldamaty, Ibraheim, Alotaibi, Abdelmegeid, Shukry and Elolimy

Since the medication is still undergoing clinical testing, official monthly retail pricing, insurance coverage criteria, and manufacturer assistance programs have not yet been established

Analyses were performed in RStudio version 2023.03.0 + 386 (RStudio: Integrated Development for R)

By purchasing this product, you are agreeing to cosmetic use only

The FDA analyzed data from large clinical trials and real-world studies involving more than 100,000 patients and did not identify higher rates of suicide-related outcomes or serious psychiatric side effects compared to placebo or other diabetes treatments

This mechanism of action differs from that of sulfonylurea derivatives, which stimulate insulin release even at low blood glucose concentrations, which is fraught with the development of sulfonylurea-induced hypoglycemia not only in patients with type 2 diabetes mellitus, but also in healthy individuals